[go: up one dir, main page]

NO20032726D0 - Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling derav - Google Patents

Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling derav

Info

Publication number
NO20032726D0
NO20032726D0 NO20032726A NO20032726A NO20032726D0 NO 20032726 D0 NO20032726 D0 NO 20032726D0 NO 20032726 A NO20032726 A NO 20032726A NO 20032726 A NO20032726 A NO 20032726A NO 20032726 D0 NO20032726 D0 NO 20032726D0
Authority
NO
Norway
Prior art keywords
compounds
preparation
quinazoline derivatives
medicaments containing
medicaments
Prior art date
Application number
NO20032726A
Other languages
English (en)
Other versions
NO325672B1 (no
NO20032726L (no
Inventor
Frank Himmelsbach
Elke Langkopf
Stefan Blech
Birgit Jung
Elke Baum
Flavio Solca
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7667887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032726(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20032726D0 publication Critical patent/NO20032726D0/no
Publication of NO20032726L publication Critical patent/NO20032726L/no
Publication of NO325672B1 publication Critical patent/NO325672B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20032726A 2000-12-20 2003-06-16 Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse for fremstilling av legemidler og fremgangsmate for fremstilling derav NO325672B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10063435A DE10063435A1 (de) 2000-12-20 2000-12-20 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PCT/EP2001/014569 WO2002050043A1 (de) 2000-12-20 2001-12-12 Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Publications (3)

Publication Number Publication Date
NO20032726D0 true NO20032726D0 (no) 2003-06-16
NO20032726L NO20032726L (no) 2003-06-16
NO325672B1 NO325672B1 (no) 2008-07-07

Family

ID=7667887

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20032726A NO325672B1 (no) 2000-12-20 2003-06-16 Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse for fremstilling av legemidler og fremgangsmate for fremstilling derav
NO2014003C NO2014003I2 (no) 2000-12-20 2014-02-11 Afatinib - tautomerer, stereoisomerer og salter derav, fysiologisk akseptable salter med uorganiske eller organiske syrer eller baser, fortrinnsvis et maleatsalt derav, mer fortrinnsvis et dimaletsalt derav (patentkravene 3, 4 og 5)
NO2022028C NO2022028I1 (no) 2000-12-20 2022-07-01 Afatinib - tautomers, stereoisomers og salts thereof - forlengelse SPC

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2014003C NO2014003I2 (no) 2000-12-20 2014-02-11 Afatinib - tautomerer, stereoisomerer og salter derav, fysiologisk akseptable salter med uorganiske eller organiske syrer eller baser, fortrinnsvis et maleatsalt derav, mer fortrinnsvis et dimaletsalt derav (patentkravene 3, 4 og 5)
NO2022028C NO2022028I1 (no) 2000-12-20 2022-07-01 Afatinib - tautomers, stereoisomers og salts thereof - forlengelse SPC

Country Status (39)

Country Link
EP (2) EP1345910B9 (no)
JP (1) JP3827641B2 (no)
KR (1) KR100852102B1 (no)
CN (1) CN1277822C (no)
AR (1) AR040524A1 (no)
AT (1) ATE430136T1 (no)
AU (2) AU2002219174B2 (no)
BE (1) BE2014C009I2 (no)
BG (1) BG66139B1 (no)
BR (1) BRPI0116266B8 (no)
CA (1) CA2432428C (no)
CY (2) CY1109290T1 (no)
CZ (1) CZ302721B6 (no)
DE (2) DE10063435A1 (no)
DK (1) DK1345910T3 (no)
EA (1) EA006317B1 (no)
EE (1) EE05244B1 (no)
ES (1) ES2326617T3 (no)
FR (1) FR14C0009I2 (no)
HR (1) HRP20030504B1 (no)
HU (2) HU228874B1 (no)
IL (2) IL156277A0 (no)
LT (1) LTC1345910I2 (no)
LU (1) LU92370I2 (no)
ME (1) ME02777B (no)
MX (1) MXPA03005559A (no)
MY (1) MY136086A (no)
NO (3) NO325672B1 (no)
NZ (1) NZ526918A (no)
PL (1) PL214798B1 (no)
PT (1) PT1345910E (no)
RS (1) RS50860B (no)
SI (1) SI1345910T1 (no)
SK (1) SK287573B6 (no)
TW (1) TWI295992B (no)
UA (1) UA74614C2 (no)
UY (1) UY27078A1 (no)
WO (1) WO2002050043A1 (no)
ZA (1) ZA200304141B (no)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1731511E (pt) 1999-06-21 2015-11-13 Boehringer Ingelheim Pharma Heterociclos bicíclicos, medicamentos contendo estes compostos, a sua utilização e processos para a sua preparação
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
DE10307165A1 (de) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (de) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
DE602004013806D1 (en) 2003-09-16 2008-06-26 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
HRP20110958T1 (hr) * 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006081741A1 (fr) * 2005-02-05 2006-08-10 Piaoyang Sun Dérivés de quinazoline ou leurs sels de qualité pharmaceutique, synthèse et applications médicales desdites substances
KR100832594B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
US20090306101A1 (en) 2005-11-11 2009-12-10 Flavio Solca Combination treatment of cancer comprising egfr/her2 inhibitors
EP3173084B1 (en) * 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
PT1981863E (pt) 2006-01-26 2012-12-07 Boehringer Ingelheim Int Processo para preparar derivados de quinazolina substituídos por aminocrotonilamino
SI2068880T1 (sl) 2006-09-18 2012-08-31 Boehringer Ingelheim Int Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2009211523B2 (en) 2008-02-07 2014-03-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
EP2303276B1 (en) 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
WO2010081817A1 (en) 2009-01-14 2010-07-22 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
JP2012526766A (ja) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍性及び線維性疾患の処置における新規な併用療法
US20120136004A1 (en) * 2009-05-14 2012-05-31 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
HUE044629T2 (hu) * 2009-07-06 2019-11-28 Boehringer Ingelheim Int Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
US8735409B2 (en) * 2009-12-21 2014-05-27 Qiang Zhang Quinazoline derivatives
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2012027445A1 (en) 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Methods of administering an egfr inhibitor
EP2643314B1 (en) * 2010-11-25 2016-07-13 ratiopharm GmbH Novel salts and polymorphic forms of afatinib
EP2680850B1 (en) 2011-03-04 2018-05-23 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
CN102838590B (zh) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
EP2753616A1 (en) 2011-10-06 2014-07-16 Ratiopharm GmbH Crystalline forms of afatinib di-maleate
CN103073539B (zh) * 2011-10-26 2016-05-11 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
CN104080774B (zh) 2012-01-17 2017-02-22 安斯泰来制药株式会社 吡嗪甲酰胺化合物
CN103772380A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
EP2951171A1 (en) 2013-02-01 2015-12-09 Boehringer Ingelheim International GmbH Radiolabeled quinazoline derivatives
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE058731T2 (hu) 2013-04-18 2022-09-28 Boehringer Ingelheim Int Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
CN103254182A (zh) * 2013-05-10 2013-08-21 苏州明锐医药科技有限公司 一种阿法替尼的制备方法
WO2014180271A1 (zh) * 2013-05-10 2014-11-13 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
WO2014183560A1 (zh) * 2013-05-16 2014-11-20 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN103242303B (zh) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 阿法替尼的制备方法
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN103755688B (zh) * 2013-12-24 2015-11-18 江苏奥赛康药业股份有限公司 一种阿法替尼化合物的制备方法
US9242965B2 (en) * 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015103456A1 (en) 2014-01-02 2015-07-09 Teva Pharmaceuticals International Gmbh Crystalline forms of afatinib di-maleate
CN105315263B (zh) * 2014-07-30 2018-11-27 正大天晴药业集团股份有限公司 阿法替尼中间体的合成方法
EP3023421A1 (en) 2014-11-21 2016-05-25 Sandoz Ag Crystalline forms of afatinib dimaleate
CN105801568B (zh) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
US10231973B2 (en) 2015-03-20 2019-03-19 Chai Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of quinazoline derivative and method for preparing the same
CN105175400B (zh) * 2015-09-29 2018-04-10 河北神威药业有限公司 一种阿法替尼中间体的制备方法
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib
CN106442793B (zh) * 2016-10-21 2019-05-24 河北神威药业有限公司 一种制备阿法替尼的中间体及其对映异构体的检测方法
KR20250097990A (ko) 2016-11-10 2025-06-30 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3727387A4 (en) * 2017-12-18 2021-12-15 Sterngreene, Inc. PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
CN110437163A (zh) * 2018-05-03 2019-11-12 斯特恩格林公司 作为酪氨酸激酶抑制剂的嘧啶类化合物
EP3856726A1 (en) 2018-09-25 2021-08-04 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
CN109265449B (zh) * 2018-11-07 2021-11-23 沈阳工业大学 Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
CN109824657A (zh) * 2019-03-26 2019-05-31 石药集团中奇制药技术（石家庄）有限公司 一种二马来酸阿法替尼新晶型及其制备方法和应用
CN110590682A (zh) * 2019-10-14 2019-12-20 重庆医科大学 一种制备阿法替尼杂质的方法以及制备的杂质
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN115894383A (zh) * 2021-09-30 2023-04-04 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
CN119278041A (zh) 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20250214995A1 (en) 2022-04-28 2025-07-03 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
TW202417040A (zh) 2022-06-27 2024-05-01 瑞典商阿斯特捷利康公司 涉及用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑之組合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1145614C (zh) * 1996-04-12 2004-04-14 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂，其制药用途及药物组合物
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
DE19911366A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19908567A1 (de) * 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HRP20010617A2 (en) * 1999-02-27 2002-10-31 Boehringer Ingelheim Pharma 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PT1731511E (pt) * 1999-06-21 2015-11-13 Boehringer Ingelheim Pharma Heterociclos bicíclicos, medicamentos contendo estes compostos, a sua utilização e processos para a sua preparação
ATE350378T1 (de) * 2000-04-08 2007-01-15 Boehringer Ingelheim Pharma Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
BE2014C009I2 (no) 2021-02-04
SK287573B6 (sk) 2011-03-04
KR20030071787A (ko) 2003-09-06
EP1345910A1 (de) 2003-09-24
CZ20031930A3 (cs) 2003-10-15
ES2326617T9 (es) 2014-09-10
MY136086A (en) 2008-08-29
DK1345910T3 (da) 2009-07-20
NZ526918A (en) 2006-11-30
BG107929A (bg) 2005-01-31
MEP59508A (en) 2011-05-10
EP1345910B1 (de) 2009-04-29
ZA200304141B (en) 2004-04-15
MXPA03005559A (es) 2004-10-14
AU2002219174B2 (en) 2007-09-06
HUP0301852A2 (hu) 2003-09-29
FR14C0009I1 (fr) 2014-03-07
IL156277A (en) 2009-12-24
FR14C0009I2 (fr) 2014-11-14
CA2432428C (en) 2009-09-01
BR0116266A (pt) 2004-02-17
CZ302721B6 (cs) 2011-09-21
LTC1345910I2 (lt) 2022-06-10
EA200300671A1 (ru) 2004-06-24
HU228874B1 (en) 2013-06-28
AU1917402A (en) 2002-07-01
IL156277A0 (en) 2004-01-04
AR040524A1 (es) 2005-04-13
CY2014008I1 (el) 2014-07-02
NO2014003I2 (no) 2015-10-19
JP2004516283A (ja) 2004-06-03
NO2022028I1 (no) 2022-07-01
CA2432428A1 (en) 2002-06-27
PT1345910E (pt) 2009-07-14
LU92370I2 (fr) 2014-03-31
SK7712003A3 (en) 2003-10-07
NO2014003I1 (no) 2014-06-02
CY1109290T1 (el) 2014-07-02
RS50860B (sr) 2010-08-31
HRP20030504A2 (en) 2005-06-30
BRPI0116266B8 (pt) 2021-07-27
EE05244B1 (et) 2009-12-15
PL361798A1 (en) 2004-10-04
LTPA2014005I1 (lt) 2022-05-25
WO2002050043A1 (de) 2002-06-27
DE50114874D1 (de) 2009-06-10
EP2112140A1 (de) 2009-10-28
YU49603A (sh) 2006-05-25
HRP20030504B1 (en) 2011-09-30
UY27078A1 (es) 2002-07-31
NO325672B1 (no) 2008-07-07
CN1481370A (zh) 2004-03-10
TWI295992B (en) 2008-04-21
KR100852102B1 (ko) 2008-08-13
ME02777B (me) 2011-10-10
HK1060571A1 (en) 2004-08-13
ES2326617T3 (es) 2009-10-16
HUP0301852A3 (en) 2008-03-28
PL214798B1 (pl) 2013-09-30
UA74614C2 (en) 2006-01-16
CN1277822C (zh) 2006-10-04
DE10063435A1 (de) 2002-07-04
JP3827641B2 (ja) 2006-09-27
BG66139B1 (bg) 2011-07-29
CY2014008I2 (el) 2015-12-09
BRPI0116266B1 (pt) 2017-10-31
LU92370I9 (no) 2019-01-17
HUS1400005I1 (hu) 2017-08-28
EP1345910B9 (de) 2014-06-04
EE200300300A (et) 2003-10-15
SI1345910T1 (sl) 2009-08-31
EA006317B1 (ru) 2005-10-27
ATE430136T1 (de) 2009-05-15
NO20032726L (no) 2003-06-16

Similar Documents

Publication Publication Date Title
NO20032726D0 (no) Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling derav
NO20032733L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
NO20016185D0 (no) Bicykliske heterocykler, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstillingderav
NO20030870D0 (no) Bicykliske heterocykler, medikamenter inneholdende disse, deres anvendelseog fremgansgmåte for fremstilling derav
DK1086113T3 (da) Benzothiepin-1,1-dioxidderivater, fremgangsmåde til deres fremstilling, lægemidler med indhold af disse forbindelser og deres anvendelse
EE05387B1 (et) KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
DK1112251T3 (da) Azetidinderivater, deres fremstilling og medikamenter indeholdende disse derivater
NO20024742L (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20032735L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene samt deres anvendelse
DK1523488T3 (da) Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
NO984084D0 (no) 4-Amino-pyrimidin-derivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte ved fremstilling derav
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
NO20032332L (no) Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav
DK1414816T3 (da) Stabil polymorf af flibanserin, teknisk fremgangsmåde til fremstilling deraf og anvendelse deraf til lægemiddelfremstilling
DK1674456T3 (da) Nye 1,4-benzothiazepin-1,1-dioxid-derivater med forbedrede egenskaber, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
DK1117661T3 (da) Propanolaminderivater substitueret med heterocycliske grupper, fremgangsmåde til deres fremstilling, farmaceutiske præparater indeholdende disse forbindelser og deres anvendelse
NO20015659D0 (no) Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
NO20016404D0 (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20033120D0 (no) 2-arylimino-2,3-dihydrotiazolderivater, fremgangsmater for fremstilling derav og terapeutisk anvendelse derav
NO20024105D0 (no) Memnopeptider, fremgangsmåte for deres fremstilling og anvendelse av disse
DK1241169T3 (da) Isoindoloindolonforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1341758T3 (da) Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: GIOTRIT; REG.NO/DATE: EU/1/13/879/001-012 2013.10.16; FIRST REG.NO/DATE: EU/1/13/879/001-012 2013.09.25

Spc suppl protection certif: 2014003

Filing date: 20140211

Extension date: 20261212

MK1K Patent expired
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: AFATINIB - TAUTOMERS STEREOISOMERS OG SALTS THEREOF - FORLENGELSE SPC; REG. NO/DATE: EU/1/13/879/001-012 20131016

Spc suppl protection certif: 2022028

Filing date: 20220701